5-fluorouracil
Phase
Phase3Study status
Active not recruitingView details
Revolution Medicines, Inc.
IndicationPancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma
Estimated study completion2027-12
Cash and cash equivalents · Restricted cash and marketable securities excluded
Cash verified Nov 16, 2026
Next verified event · Clinical readout window
Postponed to a later window
Previous: Q4 2026 · quarter precision
Announced Aug 5, 2026
Previous official sourceThe company continues to evaluate multiple combination approaches in CRC, including RAS(ON) inhibitor doublets and combinations with standard of care and other investigational therapies. The company expects to provide updated clinical data and additional visibility into its CRC development strategy during the fourth quarter of 2026.
Current: H1 2027 · half precision
Announced Nov 4, 2026
Current official sourceUnder the companies’ existing agreement, BeOne Medicines is funding and conducting the trial on Revolution Medicines’ behalf. Revolution Medicines expects to provide a clinical data update from its earlier phase CRC studies along with the RASonate 312 trial design in the first half of 2027.
Announced Nov 4, 2026 · Announced window
Official announcementUnder the companies’ existing agreement, BeOne Medicines is funding and conducting the trial on Revolution Medicines’ behalf. Revolution Medicines expects to provide a clinical data update from its earlier phase CRC studies along with the RASonate 312 trial design in the first half of 2027.
Clinical readout window
Announced Nov 4, 2026 · Announced window
Official announcementDevelopment of daraxonrasib in previously treated RAS mutant NSCLC continues to advance. Global enrollment in RASolve 301, the Phase 3 trial evaluating daraxonrasib in this setting, is winding down with all sites expected to close enrollment by the end of November 2026, supporting an anticipated initial readout in 2027. Previously reported Phase 1/2 clinical data evaluating daraxonrasib in RAS mutant NSCLC were publi
Clinical readout window
Announced Nov 4, 2026 · Announced window
Official announcementThe company continues enrollment in the ongoing first-in-human trial evaluating RMC-5127, its oral RAS(ON) G12V-selective, noncovalent inhibitor, and is nearing selection of a candidate recommended Phase 2 dose. The company expects to report initial clinical monotherapy data in 2027.
37 programs · 19 verified studies
| Company | Drug | Indication | Phase | Study status | Timing | Registry |
|---|---|---|---|---|---|---|
| RVMD Revolution Medicines, Inc. | 5-fluorouracil | Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma | Phase3 | Active not recruiting | Estimated study completion2027-12 | NCT06625320 |
| RVMD Revolution Medicines, Inc. | 5-fluorouracil | Pancreatic Cancer; Pancreatic Cancer Metastatic; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatic Adenocarcinoma Metastatic; Pancreatic Adenocarcinoma; Pancreatic Adenosquamous Carcinoma | Phase3 | Recruiting | Estimated study completion2030-04-22 | NCT07621718 |
| RVMD Revolution Medicines, Inc. | bevacizumab | Colorectal Cancer; CRC; Pancreatic Ductal Adenocarcinoma; PDAC; Gastrointestinal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma | Phase1 / Phase2 | Recruiting | Estimated study completion2030-03-30 | NCT06445062 |
| RVMD Revolution Medicines, Inc. | Carboplatin | Non-Small Cell Lung Cancer, NSCLC; KRAS, NRAS, HRAS-mutated NSCLC; KRAS G12C-mutated Solid Tumors, Lung Cancer; Lung Cancer Stage IV, Advanced Solid Tumor, Cancer; RAS G12D-mutated NSCLC | Phase1 / Phase2 | Recruiting | Estimated study completion2028-12 | NCT06162221 |
| RVMD Revolution Medicines, Inc. | Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only) | Advanced Solid Tumors; Metastatic Solid Tumors; Non-small Cell Lung Cancer (NSCLC); NSCLC; Colorectal Cancer (CRC); CRC | Phase1 / Phase2 | Recruiting | Estimated study completion2029-05 | NCT07397338 |
| RVMD Revolution Medicines, Inc. | Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only) | Advanced Solid Tumors; Metastatic Solid Tumors; Non-small Cell Lung Cancer (NSCLC); NSCLC; Colorectal Cancer (CRC); CRC | Phase1 / Phase2 | Recruiting | Estimated study completion2029-05 | NCT07397338 |
| RVMD Revolution Medicines, Inc. | cetuximab | Colorectal Cancer; CRC; Pancreatic Ductal Adenocarcinoma; PDAC; Gastrointestinal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma | Phase1 / Phase2 | Recruiting | Estimated study completion2030-03-30 | NCT06445062 |
| RVMD Revolution Medicines, Inc. | cetuximab | Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Adenocarcinoma; Pancreatic Ductal Adenocarcinoma (PDAC); PDAC; CRC; NSCLC; Pancreatic Cancer; Lung Cancer (NSCLC); Advanced Solid Tumors | Phase1 | Recruiting | Estimated study completion2028-10 | NCT07349537 |
| RVMD Revolution Medicines, Inc. | cetuximab (Cohort C2 Only) | Advanced Solid Tumors; Metastatic Solid Tumors; Non-small Cell Lung Cancer (NSCLC); NSCLC; Colorectal Cancer (CRC); CRC | Phase1 / Phase2 | Recruiting | Estimated study completion2029-05 | NCT07397338 |
| RVMD Revolution Medicines, Inc. | Cisplatin | Non-Small Cell Lung Cancer, NSCLC; KRAS, NRAS, HRAS-mutated NSCLC; KRAS G12C-mutated Solid Tumors, Lung Cancer; Lung Cancer Stage IV, Advanced Solid Tumor, Cancer; RAS G12D-mutated NSCLC | Phase1 / Phase2 | Recruiting | Estimated study completion2028-12 | NCT06162221 |
Phase
Phase3Study status
Active not recruitingRevolution Medicines, Inc.
IndicationPancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma
Estimated study completion2027-12
Phase
Phase3Study status
RecruitingRevolution Medicines, Inc.
IndicationPancreatic Cancer; Pancreatic Cancer Metastatic; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; Pancreatic Ductal Adenocarcinoma (PDAC); Pancreatic Adenocarcinoma Metastatic; Pancreatic Adenocarcinoma; Pancreatic Adenosquamous Carcinoma
Estimated study completion2030-04-22
Phase
Phase1 / Phase2Study status
RecruitingRevolution Medicines, Inc.
IndicationColorectal Cancer; CRC; Pancreatic Ductal Adenocarcinoma; PDAC; Gastrointestinal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma
Estimated study completion2030-03-30
Phase
Phase1 / Phase2Study status
RecruitingRevolution Medicines, Inc.
IndicationNon-Small Cell Lung Cancer, NSCLC; KRAS, NRAS, HRAS-mutated NSCLC; KRAS G12C-mutated Solid Tumors, Lung Cancer; Lung Cancer Stage IV, Advanced Solid Tumor, Cancer; RAS G12D-mutated NSCLC
Estimated study completion2028-12
Phase
Phase1 / Phase2Study status
RecruitingRevolution Medicines, Inc.
IndicationAdvanced Solid Tumors; Metastatic Solid Tumors; Non-small Cell Lung Cancer (NSCLC); NSCLC; Colorectal Cancer (CRC); CRC
Estimated study completion2029-05
Phase
Phase1 / Phase2Study status
RecruitingRevolution Medicines, Inc.
IndicationAdvanced Solid Tumors; Metastatic Solid Tumors; Non-small Cell Lung Cancer (NSCLC); NSCLC; Colorectal Cancer (CRC); CRC
Estimated study completion2029-05
Phase
Phase1 / Phase2Study status
RecruitingRevolution Medicines, Inc.
IndicationColorectal Cancer; CRC; Pancreatic Ductal Adenocarcinoma; PDAC; Gastrointestinal Cancer; Metastatic Pancreatic Ductal Adenocarcinoma
Estimated study completion2030-03-30
Phase
Phase1Study status
RecruitingRevolution Medicines, Inc.
IndicationNon-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Adenocarcinoma; Pancreatic Ductal Adenocarcinoma (PDAC); PDAC; CRC; NSCLC; Pancreatic Cancer; Lung Cancer (NSCLC); Advanced Solid Tumors
Estimated study completion2028-10
Phase
Phase1 / Phase2Study status
RecruitingRevolution Medicines, Inc.
IndicationAdvanced Solid Tumors; Metastatic Solid Tumors; Non-small Cell Lung Cancer (NSCLC); NSCLC; Colorectal Cancer (CRC); CRC
Estimated study completion2029-05
Phase
Phase1 / Phase2Study status
RecruitingRevolution Medicines, Inc.
IndicationNon-Small Cell Lung Cancer, NSCLC; KRAS, NRAS, HRAS-mutated NSCLC; KRAS G12C-mutated Solid Tumors, Lung Cancer; Lung Cancer Stage IV, Advanced Solid Tumor, Cancer; RAS G12D-mutated NSCLC
Estimated study completion2028-12
6 unverified sponsor matches remain unlinked.